Literature DB >> 1492426

Metabolism of the anti-psoriatic agent 5-methoxypsoralen in humans: comparison with rat and dog.

B A John1, L F Chasseaud, S G Wood, P Forlot.   

Abstract

1. Single oral doses of 14C-5-methoxypsoralen (5-MOP) to human subjects (50 mg), rats (1 mg/kg) and dogs (1 mg/kg) were fairly well absorbed but subjected to extensive first-pass metabolism, at least in rat and human. Means of 62, 51 and 40% dose in urine and 31, 38 and 48% dose in faeces, were excreted by humans (during 5 days), rats (3 days) and dogs (1 day), respectively. In dogs, faecal 14C was probably derived, in part, from biliary excreted material. 2. Total 14C in human plasma reached peak concentrations after 2 h (mean 235 ng 5-MOP equivalent/ml) and declined relatively slowly, to about 60% of this value within 24 h. Unchanged 5-MOP was not detected in plasma using h.p.l.c. (< 5 ng/ml). 3. Tissue concentrations of 14C were generally greater in dogs than rats and reached peak levels at 1 h in dogs but at 24 h in rats. Apart from liver and bile, dog tissue 14C concentrations were lower than those in the corresponding plasma, whereas in rat they were lower only until the time of peak concentrations, after which they were generally greater. 4. 5-MOP was extensively metabolized in all three species. The major 14C-components in human and dog urine were glucuronic acid conjugates, mainly of an arylacetic acid and arylalcohols, resulting from initial oxidative metabolism of the furan ring of 5-MOP. In rat, these metabolites were excreted mainly unconjugated. An unusual metabolite was formed by reduction of the lactone moiety of 5-MOP, probably by the gut flora, giving rise to an arylpropionic acid, excreted as a glucuronic acid conjugate in the urine of all three species. 5. Unchanged drug was a very minor component of human and rat plasma, but a major component of dog plasma. In all three species, circulating 14C-metabolites were similar to those in the urine but were present mainly unconjugated. On the basis of these data, the metabolic fate of 5-MOP in humans was more similar to that in dog than to that in rat, although humans appeared to metabolize 5-MOP more rapidly than did dog.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1492426     DOI: 10.3109/00498259209053162

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  7 in total

1.  Identification of phase-I metabolites and chronic toxicity study of the Kv1.3 blocker PAP-1 (5-(4-phenoxybutoxy)psoralen) in the rat.

Authors:  B Hao; Z-W Chen; X-J Zhou; P I Zimin; G P Miljanich; H Wulff; Y-X Wang
Journal:  Xenobiotica       Date:  2010-11-11       Impact factor: 1.908

2.  Contamination of deconjugation enzymes derived from Helix pomatia with the plant bioactive compounds 3,3'-diindolylmethane, 5-methoxypsoralen, and 8-methoxypsoralen.

Authors:  Cheryl E Ainslie-Waldman; Scott W Simpkins; Pramod Upadhyaya; Steven G Carmella; Stephen S Hecht; Sabrina P Trudo
Journal:  Food Chem Toxicol       Date:  2013-08-30       Impact factor: 6.023

3.  CYP1A2, GSTM1, and GSTT1 polymorphisms and diet effects on CYP1A2 activity in a crossover feeding trial.

Authors:  Sabrina Peterson; Yvonne Schwarz; Shuying S Li; Lin Li; Irena B King; Chu Chen; David L Eaton; John D Potter; Johanna W Lampe
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-10-20       Impact factor: 4.254

4.  Inhibition of melatonin metabolism in humans induced by chemical components from herbs and effective prediction of this risk using a computational model.

Authors:  Chao Wang; Xiaokui Huo; Xiangge Tian; Min Xu; Peipei Dong; Zhilin Luan; Xiaobo Wang; Baojing Zhang; Bo Zhang; Shanshan Huang; Sa Deng; Xiaochi Ma
Journal:  Br J Pharmacol       Date:  2016-10-10       Impact factor: 8.739

Review 5.  Pharmacological Properties of Bergapten: Mechanistic and Therapeutic Aspects.

Authors:  Maria Magdalena Quetglas-Llabrés; Cristina Quispe; Jesús Herrera-Bravo; Marcelo D Catarino; Olívia R Pereira; Susana M Cardoso; Kamal Dua; Dinesh Kumar Chellappan; Kavita Pabreja; Saurabh Satija; Meenu Mehta; Antoni Sureda; Miquel Martorell; Dinara Satmbekova; Balakyz Yeskaliyeva; Javad Sharifi-Rad; Naeem Rasool; Monica Butnariu; Iulia Cristina Bagiu; Radu Vasile Bagiu; Daniela Calina; William C Cho
Journal:  Oxid Med Cell Longev       Date:  2022-04-25       Impact factor: 7.310

Review 6.  5-Methoxypsoralen. A review of its effects in psoriasis and vitiligo.

Authors:  W McNeely; K L Goa
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

7.  Food-induced increase in bioavailability of 5-methoxypsoralen.

Authors:  H Ehrsson; I Wallin; A M Ros; S Eksborg; M Berg
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.